Announcement of a large-scale exercise of stock acquisition rights and disclosure of monthly and cumulative exercise status. Total issued units are 240,000; the recent large-scale exercise was 26,700 units (11.1%), and monthly exercise amounted to 71,700 units (29.9%). Unexercised rights remain outstanding.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4883","jir_company_name":"Modalis Therapeutics Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4883-20261001-01.pdf","jir_short_summary":"Announcement of a large-scale exercise of stock acquisition rights and disclosure of monthly and cumulative exercise status. Total issued units are 240,000; the recent large-scale exercise was 26,700 units (11.1%), and monthly exercise amounted to 71,700 units (29.9%). Unexercised rights remain outstanding.","jir_summary":"### Large-Scale Exercise Status of Stock Acquisition Rights\nThe subject stock acquisition rights (19th series, with exercise price adjustment clause) were issued by allotment to EVO FUND, and a large-scale exercise of the rights was observed between September 11, 2026 and September 30, 2026. Against the total issuance of 240,000 units, the recent exercise amounted to 26,700 units (11.1%), and monthly exercise reached 71,700 units (29.9%), marking a high level. Unexercised rights stood at 67,000 units at the end of the month.\n\n### Future Impact and Exercise Restriction Status\nThis exercise may contribute to dilution relative to the total issuance; however, compliance with exercise restrictions at present is disclosed as 7.4% based on listing regulations. Future exercise trends are TBD, and additional disclosures are planned.","jir_financial_highlights":"Total number of stock acquisition rights issued: 240,000 shares\nNumber of stock acquisition rights exercised since the previous disclosure: 26,700 units\nNumber of unexercised stock acquisition rights at the time of the previous disclosure: 93,700 units (9,370,000 shares)\nNumber of unexercised stock acquisition rights at present: 67,000 units (6,700,000 shares)\nNumber of stock acquisition rights exercised during the subject month: 71,700 units","jir_category":"","jir_hashtags":"#ModalisTherapeutics, #StockAcquisitionRights, #StockOptions, #CapitalPolicy","jir_key_figures":"Total number of stock acquisition rights issued: 240,000 shares\nNumber exercised this time: 26,700 units\nMonthly exercised number: 71,700 units","jir_meta_title":"Modalis Therapeutics \u2014 Large-Scale Exercise and Monthly Exercise Status of Stock Acquisition Rights | September 2026","jir_meta_description":"Modalis Therapeutics announced a large-scale exercise of the 19th stock acquisition rights and the September monthly exercise status. Of 240,000 issued units, 26,700 were exercised in the recent event and 71,700 in the month. Unexercised rights total 67,000 units.","jir_og_title":"Modalis Therapeutics \u2014 Large-Scale Exercise and Monthly Exercise Status of Stock Acquisition Rights | September 2026","jir_og_description":"Modalis Therapeutics announced a large-scale exercise of the 19th stock acquisition rights. Of 240,000 issued units, 26,700 were exercised in the recent event and 71,700 in the month. Unexercised rights total 67,000 units.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60005,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-125715","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n